mobile-logo
 

All News

03 Jan

Strategic collaboration

Investor News / RNS

Physiomics plc (AIM: PYC), is pleased to announce that it has entered into a strategic collaboration with the Medicines Discovery Catapult. Physiomics will be part of the “Virtual R&D” network of advisors and available to provide advice to the many small biotechnology companies supported by Medicines Discovery Catapult. Click here to read in full.  ...

Read More
17 Dec

Renewal of Agreement with Merck

Investor News / RNS

Physiomics plc (Oxford, UK) is pleased to announce that, following a successful collaboration this year and pursuant to the Master Services Agreement signed with Merck, a leading science and technology company, in November 2017, it has agreed with its client a program of work for the next calendar year. Click here to read in full....

Read More
20 Nov

Results of AGM

Investor News / RNS

The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to shareholders were passed. Please click here to read in full....

Read More
29 Oct

Physiomics to host stand at EORTC Dublin

Other News

Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for Research and Treatment of Cancer (“EORTC”) acts as a hub for a network of over 930 institutions in 30 countries focused on translational and clinical cancer research. The Symposium is co-hosted by EORTC, the National Cancer Institute (NCI) and the American Association for...

Read More
15 Oct

Dispatch of Annual Report and Shareholder Circular

Other News

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report for the financial year ended 30th June 2018 and a Circular in relation to its forthcoming Annual General Meeting Please click here to read in full....

Read More
08 Oct

Final Results for the year ended 30 June 2018

Other News

Chairman and Chief Executive Officer’s Statement Introduction We are very pleased to report on a year when we generated the highest total income in the Company’s history.  Having secured the agreement with Merck KGaA in November 2017, we were able to turn our attention to our pipeline and, leveraging the publicity generated by the Merck deal we converted two large pharmaceutical clients and a biotech client in...

Read More
09 Aug

Contract award

Other News

Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k and it is expected to complete in this calendar year. Click here to read in full....

Read More
21 Jun

Trading update

Other News

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that based on its current unaudited accounts at 20th June, it is trading ahead of market expectations for its full financial year ending 30th June 2018. Click here to read in full...

Read More